At a glance
- Originator Genelabs Technologies
- Class Antithrombotics; Vascular disorder therapies
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis; Deep vein thrombosis; Embolism; Thrombosis; Unstable angina pectoris